Constantinides I P, Pathouli C, Karvountzis G, Papadopoulos P, Varvoutsi-Constantinides M, Eliakis P, Hadziyannis S, Komninos Z
Cancer. 1985 May 15;55(10):2384-9. doi: 10.1002/1097-0142(19850515)55:10<2384::aid-cncr2820551014>3.0.co;2-3.
Serum beta-2-microglobulin (S-beta 2M) was measured at diagnosis in 44 patients with lymphocytic leukemias and 47 with malignant lymphomas. Among patients with chronic lymphocytic leukemia (CLL) S-beta 2M was raised (greater than 3 mg/l) in 74% and in 23.5% of those with acute lymphoblastic leukemia (ALL). The frequencies for non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) were 59.2% and 40%, respectively. In CLL patients high serum values correlated with large tumor mass, as estimated by Rai's clinical criteria (P less than 0.001), by total peripheral lymphocytes (r = 0.41, P less than 0.05) and by the percentage of bone marrow infiltration of the lymphocytes (P less than 0.01). A significant relation was also found in CLL patients between S-beta 2M level and survival (P less than 0.05). In ALL no association was found between S-beta 2M level with peripheral lymphoblast concentration, French-American-British (FAB) subclassification, splenomegaly, and survival. In NHL patients a significant association was found between S-beta 2M levels and stage of disease (P less than 0.01) and an obscure relation (P less than 0.1) with the presence of lymph nodes greater than 3 cm in diameter, splenomegaly, and hepatomegaly. No significant association was found between S-beta 2M level and histologic subtypes, presence of B symptoms, bone marrow involvement, and survival. In HD patients a significant association was found between the level of S-beta 2M and stage of disease (P less than 0.05) and presence of splenomegaly (P less than 0.05). No association was found between S-beta 2M level and histologic subtypes, lymph nodes greater than 3 cm in diameter, bone marrow involvement, and B symptoms. A significant relation was found between S-beta 2M level and survival in HD patients with widespread disease (P less than .025).
在44例淋巴细胞白血病患者和47例恶性淋巴瘤患者确诊时检测了血清β2-微球蛋白（S-β2M）。在慢性淋巴细胞白血病（CLL）患者中，74%的患者S-β2M升高（大于3mg/L），急性淋巴细胞白血病（ALL）患者中这一比例为23.5%。非霍奇金淋巴瘤（NHL）和霍奇金病（HD）患者中这一比例分别为59.2%和40%。在CLL患者中，根据Rai临床标准估计，高血清值与大肿瘤肿块相关（P<0.001），与外周血淋巴细胞总数相关（r=0.41，P<0.05），与淋巴细胞骨髓浸润百分比相关（P<0.01）。在CLL患者中还发现S-β2M水平与生存率之间存在显著关系（P<0.05）。在ALL患者中，未发现S-β2M水平与外周淋巴母细胞浓度、法美英（FAB）亚型、脾肿大和生存率之间存在关联。在NHL患者中，发现S-β2M水平与疾病分期之间存在显著关联（P<0.01），与直径大于3cm的淋巴结、脾肿大和肝肿大存在不明确的关系（P<0.1）。未发现S-β2M水平与组织学亚型、B症状的存在、骨髓受累和生存率之间存在显著关联。在HD患者中，发现S-β2M水平与疾病分期之间存在显著关联（P<0.05），与脾肿大的存在之间存在显著关联（P<0.05）。未发现S-β2M水平与组织学亚型、直径大于3cm的淋巴结、骨髓受累和B症状之间存在关联。在广泛播散性疾病的HD患者中，发现S-β2M水平与生存率之间存在显著关系（P<0.025）。
